Kester Capital backs management buyout of Rephine

Pharmaceutical industry consultancy firm Rephine has changed hands via a management buyout, by a team comprising the existing senior managers together with a new chief executive, chief financial officer and chair, backed by Kester Capital, a London-based private equity investor and primary buyout firm.

Life sciences senior executive Adam Sherlock, has joined Rephine as chief executive, taking over from Rino Coladangelo, who is retiring.  The current senior executives in the business, Alasdair Leckie, Chris Burman and Gaëlle Jaron, are remaining with the business in their respective leadership roles.  In addition, Maureen Coleman, who holds several executive, non-executive director and chair roles in the life sciences sector, will join as chair of the company.  Completing the incoming team is Simon Burrows, an experienced finance director, who joins as chief financial officer.

Sherlock said: “This deal is an important and significant milestone for Rephine, and we are delighted to be partnering with Kester Capital.  Rephine has huge potential for growth, and I am looking forward to leading the organisation as we move into this next phase.”

Coladangelo added: “I am proud to have led Rephine to this point and am pleased to be handing over to Adam, Maureen and the Kester team.  I am confident their experience and expertise, supported by the great existing team, will take Rephine to the next level.”

Adam Maidment, managing partner of Kester Capital, said: “Rephine provides an invaluable service to its auditees and customers through its differentiated audit library model.  We are delighted to be partnering with Adam, Maureen and the existing management team to grow the business organically and through acquisition.”

Date published: October 20, 2021

Subscriber content

To get unlimited access subscribe today


Already a subscriber? Login